EcoDrugPlus

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSSTUG00000018911
Gene Symbol: LOC115150321
3 Cross references
200 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSSTUG00000035971
Gene Symbol: LOC115196713
3 Cross references
208 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSSTUG00000032082
Gene Symbol: LOC115152037
3 Cross references
208 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSSTUG00000017263
Gene Symbol: LOC115202675
3 Cross references
211 Possible Orthologues:

Methionine Aminopeptidase 2-Like

Ensembl ID : ENSSTUG00000026865
Gene Symbol: LOC115198959
3 Cross references
215 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSSTUG00000030056
Gene Symbol: METAP2
3 Cross references
215 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSSTUG00000027251
Gene Symbol: LOC115161468
2 Cross references
206 Possible Orthologues:

Mineralocorticoid Receptor-Like

Ensembl ID : ENSSTUG00000003432
Gene Symbol: LOC115191799
3 Cross references
205 Possible Orthologues:

Mineralocorticoid Receptor-Like

Ensembl ID : ENSSTUG00000010007
Gene Symbol: LOC115202228
3 Cross references
205 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSSTUG00000013149
Gene Symbol: LOC115165075
3 Cross references
208 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSSTUG00000007822
Gene Symbol: LOC115200671
2 Cross references
204 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSSTUG00000024739
Gene Symbol: LOC115170800
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).